INMB (INmune Bio) Institutional Ownership : 30.49% (As of Dec. 15, 2024)

View and export this data going back to 2019. Start your Free Trial

What is INmune Bio Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, INmune Bio's institutional ownership is 30.49%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, INmune Bio's Insider Ownership is 20.95%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, INmune Bio's Float Percentage Of Total Shares Outstanding is 79.78%.

INmune Bio Institutional Ownership Historical Data

The historical data trend for INmune Bio's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

INmune Bio Institutional Ownership Chart

INmune Bio Historical Data

The historical data trend for INmune Bio can be seen below:

	2024-02-29	2024-03-31	2024-04-30	2024-05-31	2024-06-30	2024-07-31	2024-08-31	2024-09-30	2024-10-31	2024-11-30
Institutional Ownership	7.04	7.06	6.37	6.37	10.41	11.65	12.45	11.91	11.92	12.04

INmune Bio Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

INmune Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » INmune Bio Inc (NAS:INMB) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

N/A

Address

225 NE Mizner Boulevard, Suite 640, Boca Raton, FL, USA, 33432

Website

https://www.inmunebio.com

INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.

Executives

David J Moss	10 percent owner, officer: CFO, Treasurer & Secretary	C/O PEGASI ENERGY RESOURCES CORPORATION, 218 N. BROADWAY, SUITE 204, TYLER TX 75702
Raymond Joseph Tesi	director, 10 percent owner, officer: President & CEO	476 MASSACHUSETTS AVE, UNIT 2, BOSTON MA 02118
Scott Juda	director	325 N. LARCHMONT BLVD, SUITE 375, LOS ANGELES CA 90004
Mark William Lowdell	10 percent owner, officer: Chief Scientific Officer	THE OAK, WLX ROAD, BEAUMONT X0 CO16 0AT
Timothy J Schroeder	director	2690 DEVILS BACKBONE ROAD, CINCINNATI OH 45233
Linda F Powers	10 percent owner	7600 WISCONSIN AVENUE, SUITE 700, BETHESDA MD 20814
James Kelly Ganjei	director	10609 RIVER OAKS LANE, POTOMAC MD 20859
Marcia Allen	director	P.O. BOX 399, 2600 W. HOMESTEAD CIRCLE, WILSON WY 83014
Edgardo Jr Baracchini	director	C/O METABASIS THERAPEUTICS, 9390 TOWNE CENTRE DRIVE, BLDG. 300, SAN DIEGO CA 92121
Xencor Inc	10 percent owner	465 N. HALSTEAD ST., SUITE 200, PASADENA CA 91107
David Edmund Szymkowski	director	241 WEST PALM AVENUE, MONROVIA CA 91016